Skip to content

Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome

Transplantation of Anaerobic Cultured Human Intestinal Microbiota in Irritable Bowel Syndrome

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02857257
Acronym
ACHIM2
Enrollment
50
Registered
2016-08-05
Start date
2015-01-31
Completion date
2018-12-31
Last updated
2018-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

IBS, Microbiota

Brief summary

Patients with irritable bowel syndrome (IBS) are treated with microbiota from a human intestinal anaerobic sample cultured for decades. Patients are recruited consecutively with symptoms of IBS and serve as their own controls. After an observation time of 4 weeks, patients are recruited for a 1-week run-in and then given the cultured fecal microbiota by the duodenal route via gastroscopy. Two treatments are given within a 1-week interval. Assessment of symptoms are made before and 4 weeks after the last treatment (at 6 weeks). Additionally, fecal samples are collected for bacterial 16S ribosomal ribonucleic acid (rRNA) analysis and bacterial functional parameters (microflora-associated characteristics).

Detailed description

Diarrhea-dominated irritable bowel syndrome (IBS-D) is studied in subjects by treatment with an anaerobic human intestinal microbiota cultured for 15 years and quality controlled with a specified content of bacterial species regularly over the years. Inclusion criteria is: Diarrheal disease since at least 4 weeks, 18-80 years of age, previously unsuccessful treatment with no symptomatic relief of antidiarrheals or resins, and signed informed consent. Primary outcome was irritable bowel syndrome-symptom severity scale (IBS-SSS). Secondary outcome was Bristol stool scale (BSS). Secondary outcome: Changes in fecal microflora distribution and multiplicity as shown by the 16S ribosomal ribonucleic acid (rRNA) analysis of feces. Once eligible for the study, patients were monitored for a run-in period of one week with the IBS-SSS and the BSS plus fecal samples for analysis of bacterial species using the bacterial specific 16S rRNA differentiation. Then, the anaerobic cultured human intestinal microflora (ACHIM) was given twice with an interval of 1 week. Thereafter, patients were further monitored over 4 weeks as regards IBS-SSS and BSS. Another feces sample was also collected for bacterial 16S rRNA analysis to evaluate the microbiota diversity. The study will be evaluated using eligible subjects as their own controls by means of Wilcoxon's matched-pairs test, alternatively t-test for matched pairs. Power analysis show that 40 subjects are needed to study in order to achieve a power of 80%.

Interventions

BIOLOGICALACHIM

After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM

Sponsors

Karolinska Institutet
CollaboratorOTHER
Uppsala University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* IBS according to the Rome III criteria

Exclusion criteria

* Pregnancy * Antibiotic and probiotics within 8 weeks before inclusion * Unable to give informed consent * Immunodeficiency (drug- och disease-related)

Design outcomes

Primary

MeasureTime frame
Symptom relief according to irritable bowel syndrome-symptom severity scale (IBS-SSS)4 weeks

Secondary

MeasureTime frameDescription
Differential bacterial species population as defined by 16S RNA4 weeksDescription of different bacterial species harboring in fecal samples before and after treatment with ACHIM. Exploratory outcome measure.
Normalization of stool consistency as determined by the Bristol stool scale4 weeksNormalization as determined by the Bristol stool scale

Countries

Sweden

Contacts

Primary ContactPeter Benno, MD, PhD
Peter.Benno@endoskopienheten.se+46 705795554
Backup ContactPer Hellström, MD, PhD
Per.Hellstrom@medsci.uu.se+46 70 3727423

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 3, 2026